A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine
- PMID: 10855461
- DOI: 10.1055/s-2000-341
A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine
Abstract
The present postmarketing surveillance (PMS) study is the first large scale systematic and prospective clinical trial of pharmacotherapeutic intervention in advanced stages of dementia. Within a validation program this study aimed at demonstrating the sensitivity of the D-Scale of change (DS-C) for measuring ADL-function. Efficacy of treatment with the NMDA-antagonist memantine was investigated in 531 patients with advanced dementia employing a parallel group design that stratified patient cohorts by severity according to GDS stages (Reisberg, 1992). Efficacy was determined on two independent levels: by the assessment of the physicians' Clinical Global Impression of Change (CGI-C) at the end of a 6-week observation period, and by the assessment of change in elementary ADL-functions by the caregivers using the D-Scale-of-Change. With the D-Scale-of-Change the caregivers can assess a change in broad functional items, i.e. cognitive and motor functions and also elementary functions of daily life. The effect size of this improvement increased constantly during the observation period. Even in patients of GDS stage 7 an improvement could be measured. These results were also seen by the physicians, who recorded an overall clinical improvement in 75.5% of the patients after 6 weeks. Tolerability evaluations resulted in the ratings "very well" by 59.5% or "well" by 35.0% of the patients. No serious adverse drug reactions occurred. A correlation analysis demonstrated a high congruency of both assessments. Furthermore, the observed time course of these improvements paralleled with the time course of symptomatic benefit by effects of memantine that had been repeatedly demonstrated in randomised, double-blind, placebo-controlled studies in mild to moderate dementia. Together with the evaluation of the scale-properties of the D-Scale for assessment of severity the D-Scale and the D-Scale-of-Change can be regarded as validated.
Similar articles
-
Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.Arzneimittelforschung. 1992 Jul;42(7):904-13. Arzneimittelforschung. 1992. PMID: 1418054 Clinical Trial.
-
Memantine (Ebixa) in clinical practice - results of an observational study.Dement Geriatr Cogn Disord. 2007;24(2):111-7. doi: 10.1159/000104872. Epub 2007 Jun 29. Dement Geriatr Cogn Disord. 2007. PMID: 17622714
-
Memantine in moderate-to-severe Alzheimer's disease.N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128. N Engl J Med. 2003. PMID: 12672860 Clinical Trial.
-
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.J Clin Psychiatry. 2006;67 Suppl 3:15-22; quiz 23. J Clin Psychiatry. 2006. PMID: 16649847 Review.
-
Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. doi: 10.1097/01.wad.0000201847.29836.a5. Alzheimer Dis Assoc Disord. 2006. PMID: 16493232 Review.
Cited by
-
A Systematic Review of Nonpharmacological Interventions for Moderate to Severe Dementia: A Study Protocol for a Systematic Review and Meta-Analysis.Psychiatry Investig. 2018 Apr;15(4):417-423. doi: 10.30773/pi.2017.09.06. Epub 2018 Mar 26. Psychiatry Investig. 2018. PMID: 29669408 Free PMC article.
-
Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.Drugs Aging. 2009;26(4):321-32. doi: 10.2165/00002512-200926040-00003. Drugs Aging. 2009. PMID: 19476399
-
Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study.Prim Care Companion J Clin Psychiatry. 2006;8(5):258-63. doi: 10.4088/pcc.v08n0501. Prim Care Companion J Clin Psychiatry. 2006. PMID: 17235381 Free PMC article.
-
[Treatment options for bladder disorders in the aged].Urologe A. 2004 May;43(5):547-51. doi: 10.1007/s00120-004-0572-z. Urologe A. 2004. PMID: 15112039 Review. German.
-
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.CNS Drug Rev. 2003 Fall;9(3):275-308. doi: 10.1111/j.1527-3458.2003.tb00254.x. CNS Drug Rev. 2003. PMID: 14530799 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
